NCT06158399View on ClinicalTrials.gov

AZA Combined With RCHOP in P53-mutated DLBCL.

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
DLBCL - Diffuse Large B Cell LymphomaTP53
Interventions
DRUG

Azacitidine in combination with R-CHOP

"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"

Trial Locations (1)

361000

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
collaborator

Jiangsu Provincial People's Hospital

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

lead

The First Affiliated Hospital of Xiamen University

OTHER